Moreover, morpholino CAG oligonucleotides (25, 26) and several bioactive small molecules (27–34), which are CUG repeat binders, have been reported as potential therapeutic agents for DM1, capable of inhibiting the interactions between expanded CUG RNA and MBNL1 protein. Here, MBNL1 is linked to myotonic dystrophy type 1.